Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
<p dir="ltr">The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibod...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513516844613632 |
|---|---|
| author | Farah M. Shurrab (16324961) |
| author2 | Duaa W. Al-Sadeq (10976754) Haissam Abou-Saleh (497840) Nader Al-Dewik (4166527) Amira E. Elsharafi (18300841) Fatima M. Hamaydeh (18300844) Bushra Y. Abo Halawa (18300847) Tala M. Jamaleddin (18300850) Huda M. Abdul Hameed (18300853) Parveen B. Nizamuddin (14590613) Fathima Humaira Amanullah (18300856) Hanin I. Daas (17863886) Laith J. Abu-Raddad (9262524) Gheyath K. Nasrallah (9200525) |
| author2_role | author author author author author author author author author author author author author |
| author_facet | Farah M. Shurrab (16324961) Duaa W. Al-Sadeq (10976754) Haissam Abou-Saleh (497840) Nader Al-Dewik (4166527) Amira E. Elsharafi (18300841) Fatima M. Hamaydeh (18300844) Bushra Y. Abo Halawa (18300847) Tala M. Jamaleddin (18300850) Huda M. Abdul Hameed (18300853) Parveen B. Nizamuddin (14590613) Fathima Humaira Amanullah (18300856) Hanin I. Daas (17863886) Laith J. Abu-Raddad (9262524) Gheyath K. Nasrallah (9200525) |
| author_role | author |
| dc.creator.none.fl_str_mv | Farah M. Shurrab (16324961) Duaa W. Al-Sadeq (10976754) Haissam Abou-Saleh (497840) Nader Al-Dewik (4166527) Amira E. Elsharafi (18300841) Fatima M. Hamaydeh (18300844) Bushra Y. Abo Halawa (18300847) Tala M. Jamaleddin (18300850) Huda M. Abdul Hameed (18300853) Parveen B. Nizamuddin (14590613) Fathima Humaira Amanullah (18300856) Hanin I. Daas (17863886) Laith J. Abu-Raddad (9262524) Gheyath K. Nasrallah (9200525) |
| dc.date.none.fl_str_mv | 2022-01-25T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3390/vaccines10020191 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Assessment_of_the_Neutralizing_Antibody_Response_of_BNT162b2_and_mRNA-1273_SARS-CoV-2_Vaccines_in_Na_ve_and_Previously_Infected_Individuals_A_Comparative_Study/25539625 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Immunology Pharmacology and pharmaceutical sciences neutralizing antibodies Pfizer-BNT162b2 Moderna-mRNA-1273 SARS-CoV-2 vaccine |
| dc.title.none.fl_str_mv | Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates with the degree of protection. However, the difference between the immune response in naïve mRNA-vaccinated and previously infected (PI) individuals is not well studied. We investigated the level of NAbs in naïve and PI individuals after 1 to 26 (median = 6) weeks of the second dose of BNT162b2 or mRNA-1273 vaccination. The naïve mRNA-1273 vaccinated group (n = 68) generated significantly higher (~2-fold, p ≤ 0.001) NAbs than the naïve BNT162b2 (n = 358) group. The P -vaccinated group (n = 42) generated significantly higher (~3-fold; p ≤ 0.001) NAbs levels than the naïve-BNT162b2 (n = 426). Additionally, the older age groups produced a significantly higher levels of antibodies than the young age group (<30) (p = 0.0007). Our results showed that mRNA-1273 generated a higher NAbs response than the BNT162b2 vaccine, and the PI group generated the highest level of NAbs response regardless of the type of vaccine.</p><h2>Other Information</h2><p dir="ltr">Published in: Vaccines<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/vaccines10020191" target="_blank">https://dx.doi.org/10.3390/vaccines10020191</a></p><p><br></p><p dir="ltr">Additional institutions affiliated with: Hamad Medical Corporation, Interim Translational Research Institute - HMC, Hamad General Hospital - HMC, Women's Wellness and Research Center - HMC</p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_a4502a1f2e6dacffd1b1285c9753a07f |
| identifier_str_mv | 10.3390/vaccines10020191 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25539625 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative StudyFarah M. Shurrab (16324961)Duaa W. Al-Sadeq (10976754)Haissam Abou-Saleh (497840)Nader Al-Dewik (4166527)Amira E. Elsharafi (18300841)Fatima M. Hamaydeh (18300844)Bushra Y. Abo Halawa (18300847)Tala M. Jamaleddin (18300850)Huda M. Abdul Hameed (18300853)Parveen B. Nizamuddin (14590613)Fathima Humaira Amanullah (18300856)Hanin I. Daas (17863886)Laith J. Abu-Raddad (9262524)Gheyath K. Nasrallah (9200525)Biomedical and clinical sciencesImmunologyPharmacology and pharmaceutical sciencesneutralizing antibodiesPfizer-BNT162b2Moderna-mRNA-1273SARS-CoV-2vaccine<p dir="ltr">The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates with the degree of protection. However, the difference between the immune response in naïve mRNA-vaccinated and previously infected (PI) individuals is not well studied. We investigated the level of NAbs in naïve and PI individuals after 1 to 26 (median = 6) weeks of the second dose of BNT162b2 or mRNA-1273 vaccination. The naïve mRNA-1273 vaccinated group (n = 68) generated significantly higher (~2-fold, p ≤ 0.001) NAbs than the naïve BNT162b2 (n = 358) group. The P -vaccinated group (n = 42) generated significantly higher (~3-fold; p ≤ 0.001) NAbs levels than the naïve-BNT162b2 (n = 426). Additionally, the older age groups produced a significantly higher levels of antibodies than the young age group (<30) (p = 0.0007). Our results showed that mRNA-1273 generated a higher NAbs response than the BNT162b2 vaccine, and the PI group generated the highest level of NAbs response regardless of the type of vaccine.</p><h2>Other Information</h2><p dir="ltr">Published in: Vaccines<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/vaccines10020191" target="_blank">https://dx.doi.org/10.3390/vaccines10020191</a></p><p><br></p><p dir="ltr">Additional institutions affiliated with: Hamad Medical Corporation, Interim Translational Research Institute - HMC, Hamad General Hospital - HMC, Women's Wellness and Research Center - HMC</p>2022-01-25T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3390/vaccines10020191https://figshare.com/articles/journal_contribution/Assessment_of_the_Neutralizing_Antibody_Response_of_BNT162b2_and_mRNA-1273_SARS-CoV-2_Vaccines_in_Na_ve_and_Previously_Infected_Individuals_A_Comparative_Study/25539625CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/255396252022-01-25T03:00:00Z |
| spellingShingle | Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study Farah M. Shurrab (16324961) Biomedical and clinical sciences Immunology Pharmacology and pharmaceutical sciences neutralizing antibodies Pfizer-BNT162b2 Moderna-mRNA-1273 SARS-CoV-2 vaccine |
| status_str | publishedVersion |
| title | Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study |
| title_full | Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study |
| title_fullStr | Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study |
| title_full_unstemmed | Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study |
| title_short | Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study |
| title_sort | Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study |
| topic | Biomedical and clinical sciences Immunology Pharmacology and pharmaceutical sciences neutralizing antibodies Pfizer-BNT162b2 Moderna-mRNA-1273 SARS-CoV-2 vaccine |